Abstract
Background Development of an effective vaccine against HIV-1 is challenging due to various viral evolutionary mechanisms to evade human immune system. The partial efficacy of the recent RV144 vaccine efficacy trial in Thailand provides hope for improvements of vaccine regimens for higher efficacy. A Phase IIb proof-of-concept clinical trial in the Republic of South Africa (RSA) is planned to confirm and extend the results of the RV144 trial with the vaccine strategy of poxvirus vector prime plus envelope protein boost.
Highlights
Scalable and robust purification of two HIV-1 subtype C gp120 monomer subunit antigens for phase II clinical trial in Republic of South Africa
Development of an effective vaccine against HIV-1 is challenging due to various viral evolutionary mechanisms to evade human immune system
ConclusionPurified gp120 monomers were stable, either alone or in combination, and when formulated with adjuvant MF59
Summary
Development of an effective vaccine against HIV-1 is challenging due to various viral evolutionary mechanisms to evade human immune system. A Phase IIb proof-of-concept clinical trial in the Republic of South Africa (RSA) is planned to confirm and extend the results of the RV144 trial with the vaccine strategy of poxvirus vector prime plus envelope protein boost
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
